Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Introduction</h3><p>Traditional cancer therapy has many disadvantages such as low selectivity and high toxicity of chemotherapy, as well as insufficient efficacy of targeted therapy. To enhance the cytotoxic effect and targeting ability, while reducing the toxicity of antitumor drugs, an antibody drug conjugate (ADC) was developed to deliver small molecular cytotoxic payloads directly to tumor cells by binding to specific antibodies via linkers.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Method</h3><p>By reviewing published literature and the current progress of ADCs, we aimed to summarize the basic characteristics, clinical progress, and challenges of ADCs to provide a reference for clinical practice and further research.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>ADC is a conjugate composed of three fundamental components, including monoclonal antibodies, cytotoxic payloads, and stable linkers. The mechanisms of ADC including the classical internalization pathway, antitumor activity of antibodies, bystander effect, and non-internalizing mechanism. With the development of new drugs and advances in technology, various ADCs have achieved clinical efficacy. To date, nine ADCs have received US Food and Drug Administration (FDA) approval in the field of hematologic tumors and solid tumors, which have become routine clinical treatments.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>ADC has changed traditional treatment patterns for cancer patients, which enable the same treatment for pancreatic cancer patients and promote individualized precision treatment. Further exploration of indications could focus on early-stage cancer patients and combined therapy settings. Besides, the mechanisms of drug resistance, manufacturing techniques, optimized treatment regimens, and appropriate patient selection remain the major topics.</p></section>

Duocarmycin-based antibody–drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress

A Comprehensive Review of the Antitumor Properties and Mechanistic Insights of Duocarmycin Analogs

Antibody-drug Conjugate PCMC1D3-Duocarmycin SA as a Novel Therapeutic Entity for Targeted Treatment of Cancers Aberrantly Expressing MET Receptor Tyrosine Kinase

Drug conjugate-based anticancer therapy - Current status and perspectives

Development of antibody-drug conjugates in cancer: Overview and prospects

Antibody drug conjugate: the “biological missile” for targeted cancer therapy

Targeting cancer with antibody-drug conjugates: Promises and challenges

Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions

The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively

Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985)

Unlocking the potential of antibody–drug conjugates for cancer therapy

Antibody–Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence

The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads

Research progress on novel antibody drug conjugates in cancer therapy

Antibody-drug Conjugates and Their Application in the Treatment of Hematological Malignancies

A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers

Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies

Antibody-drug Conjugates: Design and Clinical Progress

Development of antibody-drug conjugates as targeted cancer therapeutics

Development, efficacy and side effects of antibody‑drug conjugates for cancer therapy (Review)

Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice